Top 35 Medical Device Startup Investors in Denmark

PreSeed Ventures is the biggest and most succesful early stage investor in Denmark. For more than 20 years, PreSeed Ventures have assisted and financed talented entrepreneurs with early-stage investments, and we hold more than 70 companies in our portfolio.

Seed Capital invests in Danish tech businesses with global ambitions. We are focused on "late seed"-stage companies, typically investing 1-3 MEUR in rounds of 1-6 MEUR. Proud backers of Trustpilot, Vivino, Lunar, Templafy, Dixa, Forecast, and many other great companies.

BioInnovation Institute is a biotechnology startup that offers entrepreneurs and researchers in life science. Early-stage life science start-ups are supported with up to 10 million DKK in funding, business acceleration, network, labs, and office space. It helps to early-stage start-ups within human health and planetary health. The startup'smission is to use its knowledge, network, funding, and infrastructure to incubate world-class life science and catalyze the commercialization of new solutions through start-ups.BioInnovation Institute was founded in 2018 and is based in Denmark.

Vaekstfonden – The Danish Growth Fund – is the Danish state's investment fund. We strive to improve access to risk capital to enable Danish businesses to innovate, and to generate growth and new jobs. In close collaboration with banks and domestic and international private investors, we finance companies from all sectors nation-wide. We canaccompany you for the entire journey – from your company’s infancy through growth phases to expansion abroad and even to an initial public offering.

Vaekstfonden – The Danish Growth Fund – is the Danish state's investment fund. We strive to improve access to risk capital to enable Danish businesses to innovate, and to generate growth and new jobs. In close collaboration with banks and domestic and international private investors, we finance companies from all sectors nation-wide. We canaccompany you for the entire journey – from your company’s infancy through growth phases to expansion abroad and even to an initial public offering.

People Ventures are your dreamcast team of co-founders, investors, executives, engineers, academics and industry experts. Together with talented entrepreneurs — We shape fantastic businesses through operational and commercial execution.

Novo Holdings is a world-leading life science investor with a focus on creating long-term value.

Vaekstfonden makes equity investments in Danish companies with a track record as well as in young entrepreneurial, innovative enterprises with an ambition for global growth.

Crista Galli Ventures invests in ambitious European healthtech companies at Seed and Series A. Our deep medical expertise, powerful network and agile approach enable founders to build important, world-class healthcare businesses.

Stine Molgaard Sorensen is the Co-founder and COO of Radiobotics.

West Hill Corporate Finance is a leading private equity venture capital firm providing EIS qualifying high-growth investments to private individuals.

Alumni Ventures offers diversified venture portfolios to accredited investors into highly competitive deals that individuals typically do not have access to on their own.

We invest in growth companies in the "late-stage venture/growth capital" phase, focussed on the technology and healthtech sectors.

Digital Leaders Ventures (DLV) is a European Venture Capital Fund based in Luxembourg. DLV is investing in tech companies disrupting industries on a global level. They focus on entrepreneurs from Europe who go global from day one, combining a scalable business model with high growth and large demand.

Chr. Augustinus Fabrikker operates as an investment management firm with a core focus on dedicated ownership of Danish businesses. Founded in 1750, Chr. Augustinus Fabrikker has a capital base of more than 30 billion, a significant player in the Danish business community. It is owned by the Augustinus Foundation, which is one of Denmark'slargest cultural foundations, and also makes significant contributions to research and social initiatives.

GoBeyond is a FinTech company transforming angel investing into a new scalable asset class for small and large, novice to experienced investors. It offers a unique deal platform, portfolio tools, syndication/pooling, due diligence, investment monitoring services, training and certified deal leaders.Its clients are individuals, familyoffices, professional groups and corporations. It is active in the EU, Switzerland and the US. GoBeyond also offers educational training modules for angel investors in 11 categories.

Peter Sandberg is a co-founder of Nordic Secondary Fund, and a venture partner at Startup Wise Guys. He has extensive experience as a Business Angel and in asset management.

Seventure Partners is a French venture capital firm targeting in information and communication technology, and life sciences companies. It funds innovation and participates in the entrepreneurial adventure, alongside entrepreneurs and sharing their passion.Founded in 1997, Seventure Partners is one of the European leaders in venture capital, with€ 660 million under management as of December 31, 2016. It is an active partner of innovative companies that, according to the management team, show strong growth potential and evolving in two fields of activity: Digital Technologies and Life Sciences. With more than 20 employees, including some 15 investors, Seventure Partners has a proven track record and in-depth expertise in technology, entrepreneurship, and various private equity operations.Seventure's goal is to identify and support the development of tomorrow's European leaders in order to accelerate their growth. To do this, the firm provides entrepreneurs with the expertise, networks, and know-how of its internal team of investors.

Lars Marcher - Chairman of the Board @ System C Healthcare

Norgine Ventures was started in 2012 to diversify Norgine’s activities and foster innovation in the healthcare sector. Norgine Ventures provides debt and debt-like financing to innovative, fast-growing companies in the fields of healthcare and life sciences, in Europe and the US. Norgine Ventures is backed by Norgine, a fully integrated, private,European healthcare company with over 110 years of experience in the pharma space.Norgine Ventures has full access to Norgine’s technical capabilities for evaluating investment opportunities, although the business is aimed at achieving a financial return rather than funding opportunities of strategic interest to Norgine.To date, Norgine Ventures has invested in a number of businesses, including specialty pharma, diagnostic and medical device companies, at various stages of their life cycle, both in Europe and in the US.

Novo A/S is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, and the holding company of the Novo Group and as such the majority shareholder in the publicly listed companies Novo Nordisk A/S and Novozymes A/S.Novo A/S was established in 1999 prior to the demerger of Novo NordiskA/S, where Novozymes A/S was established as a stand-alone publicly listed company. Novo's purpose and objectives are to manage the Foundation's financial assets and to ensure the Foundation sufficient dividends to cover its grant obligations for medical and scientific research etc. in Scandinavia.Novo A/S attains these objectives through:compliance with the rules and principles which are set out in the Articles of Association of the Novo Nordisk Foundation regarding exercise of the voting rights of A and B shares in Novo Nordisk A/S and Novozymes A/S, respectively, assurance that all companies in which the company has a material influence actively contribute to the development of the Novo Group and operate their business in accordance with the visions and values of the Novo Group, maintenance of a material influence on Novo Nordisk A/S and Novozymes A/S, and investment and financing business including placing of capital in companies and real property domestically and abroad.Novo’s overall investment strategy is thus to maintain ownership of Novo Nordisk’ and Novozymes’ shares at a level just above 25% and to invest dividends from these companies and other income in the life science area as well as in a broad portfolio of financial assets.Novo A/S has since 1999 established itself as an international venture capital partner in the life science area and has invested in over 50 companies in Denmark, Europe and North America. Through its financial investment activities Novo A/S seeks to spread the company’s total financial risk and at the same time to ensure a high return taking into consideration the chosen risk profile. In 2007 Novo A/S together with the Novo Nordisk Foundation established ‘Novo Seeds’. The new program (split into two sub-programs) is aimed at supporting early stage applied research in the life science area in Scandinavia. At the beginning of 2009 Novo A/S launched a new initiative, investing 'growth equity' into promising later stage/commercial stage life science companies. Novo A/S represents the interests of the Novo Nordisk Foundation through participation on the boards of the companies in the Novo Group.The companies in the Novo Group are members of a 'family of companies', independently managed, but sharing a set of common values as set out in the 'Charter for Companies in the Novo Group'. In the Charter these core values, commitments and management principles that companies in the Novo Group should live up to are described.

Verve Ventures has invested in more than 140 science and technology startups. We support visionary and resilient entrepreneurs from day one and are a reliable partner for the entire journey. We typically invest EUR 1-3m in early as well as later stage rounds of European high tech startups.

We deploy early stage capital to fuel the growth of need-driven health technology companies.

CBC Investment Group started in 2009 in the midst of the financial crisis. The banks were on their knees, start-ups of small and medium-sized companies - all of a sudden they saw their credit and credit promises turned into demands for quick repayment and empty words. Serious talented entrepreneurs' ideas and companies risked going completelyunnecessary. In response to this crisis, they started the CBC Investment Group.

Penny Schiffer - CEO & Co-founder @ Raized.ai

Investo Capital is a Danish venture capital firm based in Aalborg. They invest in carefully selected Danish early-growth companies within tech business areas in the broad sense. The target group is innovative companies with proof of business, strategic thinking, and strong growth prospects in Denmark. Strategic corporate concepts and competentmanagement are essential features. The investment focus is Technology, IT, SAAS- and med-tech.

Roland Berger is a Founder of Roland Berger, Munich and has been the Roland Berger GmbH's Honorary Chairman since 2010. Today, Roland Berger has grown to become one of the world's top five strategy consulting firms with 50 offices in 36 countries. The company has a workforce of 2,400 and advises leading international industrial andservice enterprises, as well as public institutions. From the company's foundation in 1967 until 2003, Roland was Chief Executive Officer of the firm, and until 2010 Chairman of the Supervisory Board. Prior to founding his strategy consultancy, Roland was employed as a consultant and ultimately partner at a leading American consulting firm based in Milan and Boston. Roland has been appointed to various expert commissions by several German state governments and the federal government. From 2007 to its dissolution in 2014, Roland was a Member of the High Level Group on Administrative Burdens under the leadership of former Bavarian State Premier Dr. Edmund Stoiber, appointed by the European Commission. Roland is a member of several supervisory boards and advisory councils of national and international companies, foundations and organizations, including Fresenius SE & Co. KGaA (Chairman of the Audit Committee), Bad Homburg; Prime Office REIT-AG, Munich (Chairman of the Supervisory Board); RCS Mediagroup S.p.A.(Vice-President), Milan, Italy. Roland also serves on several international advisory boards, including those of Deutsche Bank AG in Frankfurt, MillerBuckfire in New York and The Blackstone Group in New York. Since 1996 Roland has been a Lecturer and Visiting Professor and since 2000 Honorary Professor for Business Administration and Management Consulting at the Brandenburg Technical University in Cottbus. Furthermore, Roland was appointed a member of the Oxford Martin Commission for Future Generations in 2012. Since 2002, Roland has been on the Business Advisory Council of the State Premier of Saxony-Anhalt and was appointed to the Globalization Council Portugal by the Portuguese President Aníbal Cavaco Silva. Previously, German President Roman Herzog had appointed Roland to the President's Advisory Council for Innovation. Roland has also actively participated in over 20 federal government commissions under Helmut Kohl and Gerhard Schröder. Roland is a member of several supervisory boards and advisory councils of national and international companies, foundations and organizations and invests in many private and listed companies as well as startups. Roland was Honorary Consul General of the Republic of Finland in Bavaria and Thuringia from 1996 to 2015. Roland is Chairman of the Board of Trustees of the Roland Berger Foundation, which he set up personally with an endowment of EUR 50 million. The Roland Berger Foundation is dedicated to the global protection of human dignity and human rights. Each year it confers the Roland Berger Award for Human Dignity. The Foundation also helps gifted children and young people from underprivileged families across Germany and Italy to gain access to the best possible primary and secondary education. Outside work, Roland pursues his interest in modern art and owns a large collection of artworks, mainly by contemporary artists from Europe, the US, South America and China. Roland also loves classical music and supports the Mahler Chamber Orchestra and Bavarian State Opera, among others. Roland loves hiking and cross-country skiing, especially in the Swiss region of Engadin. Roland studied business administration in Munich and Hamburg. (MBA from the Ludwig-Maximilians-Universität, Munich).

ATP is a self-governing institution, established by the Folketing by law in 1964. ATP's Board of Directors consists of equal representatives of employers and employees and an independent chairman of the board. The ATP Group has approx. 3,000 employees. ATP is headquartered in Hillerød, customer service centers in Frederikshavn, Holstebro,Haderslev, Vordingborg, Lillerød and Hillerød, as well as offices in Copenhagen, Allerød and New York.

At Ugly Duckling Ventures, we make capital, know-how, and real-world application available to Nordic ventures at the seed & pre-seed stage. We are operational by nature and want to get in the grind as we excel at getting early-stage ventures ready for scale.

KMD Venture operates in strategic growth segments and creates and manages user driven innovation, ideas generation, and incubation in close collaboration with users, customers, and business units. KMD Venture's purpose is to invest in opportunities that would not be picked up by KMD's existing business units, but may have great strategicand financial impact for KMD and to create and execute an external partnership setup to develop an entrepreneurial and innovative environment that can have a positive influence on KMD's innovation capability.KMD Venture only invests in startups and contribute with pre-seed or seed funding and the investment must have a strategic fit with KMD. KMD Venture A/S is owned by KMD A/S.

North-East is an ambitious, global family office helping our families live with wealth in a meaningful way from our offices in Denmark and Singapore.

EIT Health is a network of best-in-class health innovators backed by the EU. We deliver solutions to enable European citizens to live longer, healthier lives.

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.

Steen Thygesen is the CEO of Audientes. He previously worked at Star as a Managing Director, Nordics. Steen Thygesen attended London Business School.

Innovation Fund Denmark invests in the development of new knowledge and technology creating growth and employment in Denmark. The Fund focuses on societal challenges, strengthens research, and increases innovation commitment within private companies.The Fund provides risk capital that enables cutting-edge initiatives to achieve resultssubstantially impacting the Danish society. Innovation Fund Denmark is also responsible for the future societal partnerships, where companies, universities, and public authorities will work together on challenges facing the society today.